Singapore, March 4 -- Taiwan-based Senhwa Biosciences, Inc. has announced the signing of a major strategic Memorandum of Understanding (MoU) with CellType, an artificial intelligence (AI)-driven biotech company backed by Y Combinator (Winter 2026).

Prior to formalising the collaboration, the foundational research underlying CellType's technology was conducted atYale Universityin collaboration with Google DeepMind, where researchers computationally predicted and experimentally validated a novel immune-modulatory mechanism of CX-4945. This strategic alliance marks a transformative milestone for Senhwa: CX-4945 is evolving from a single-target small molecule into a platform-enabling asset-"CX-4945 2.0."

Through AI-driven deep data validati...